



Regeneron to Report Third Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2016

October 7, 2016

TARRYTOWN, N.Y., Oct. 7, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that it will report its third quarter 2016 financial and operating results on Friday, November 4, 2016, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Conference Call Information

To access this call, dial (888) 771-4371 (U.S.) or (847) 585-4405 (International). A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at www.regeneron.com. A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.

Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, atopic dermatitis, pain, oncology, and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:

Investor Relations
Manisha Narasimhan, Ph.D.
914.847.5126
manisha.narasimhan@regeneron.com

Corporate Communications
Hala Mirza
914.847.3422
hala.mirza@regeneron.com

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/regeneron-to-report-third-quarter-2016-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-4-2016-300340914.html>

SOURCE Regeneron Pharmaceuticals, Inc.

News Provided by Acquire Media